Sanger GJ - Search Results

1

Increased defecation during stress or after 5-hydroxytryptophan: selective inhibition by the 5-HT(4) receptor antagonist, SB-207266.

Sanger GJ, Yoshida M, Yahyah M, Kitazumi K. Sanger GJ, et al. Br J Pharmacol. 2000 Jun;130(3):706-12. doi: 10.1038/sj.bjp.0703367. Br J Pharmacol. 2000. PMID: 10821802 Free PMC article.

2

Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: Lead identification.

Heightman TD, Scott JS, Longley M, Bordas V, Dean DK, Elliott R, Hutley G, Witherington J, Abberley L, Passingham B, Berlanga M, de Los Frailes M, Wise A, Powney B, Muir A, McKay F, Butler S, Winborn K, Gardner C, Darton J, Campbell C, Sanger G. Heightman TD, et al. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6584-7. doi: 10.1016/j.bmcl.2007.09.067. Epub 2007 Sep 25. Bioorg Med Chem Lett. 2007. PMID: 17942309

3

Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation.

Witherington J, Abberley L, Briggs MA, Collis K, Dean DK, Gaiba A, King NP, Kraus H, Shuker N, Steadman JG, Takle AK, Sanger G, Wadsworth G, Butler S, McKay F, Muir A, Winborn K, Heightman TD. Witherington J, et al. Bioorg Med Chem Lett. 2008 Mar 15;18(6):2203-5. doi: 10.1016/j.bmcl.2007.12.021. Epub 2007 Dec 15. Bioorg Med Chem Lett. 2008. PMID: 18316188

4

Synthesis and pharmacological activity of metabolites of the 5-HT(4) receptor antagonist SB-207266.

Fedouloff M, Hossner F, Voyle M, Ranson J, Powles J, Riley G, Sanger G. Fedouloff M, et al. Bioorg Med Chem. 2001 Aug;9(8):2119-28. doi: 10.1016/s0968-0896(01)00120-1. Bioorg Med Chem. 2001. PMID: 11504648

5

Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: A model of chemotherapy-related malaise?

Malik NM, Moore GB, Smith G, Liu YL, Sanger GJ, Andrews PL. Malik NM, et al. Among authors: sanger gj. Pharmacol Biochem Behav. 2006 Jan;83(1):9-20. doi: 10.1016/j.pbb.2005.11.017. Epub 2006 Jan 26. Pharmacol Biochem Behav. 2006. PMID: 16443263

6

Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility.

Broad J, Kung VW, Boundouki G, Aziz Q, De Maeyer JH, Knowles CH, Sanger GJ. Broad J, et al. Among authors: sanger gj. Br J Pharmacol. 2013 Nov;170(6):1253-61. doi: 10.1111/bph.12397. Br J Pharmacol. 2013. PMID: 24032987 Free PMC article.

7

5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats.

Smith MI, Banner SE, Sanger GJ. Smith MI, et al. Among authors: sanger gj. Neurosci Lett. 1999 Aug 13;271(1):61-4. doi: 10.1016/s0304-3940(99)00513-3. Neurosci Lett. 1999. PMID: 10471214

8

5-HT4 receptor antagonism does not affect motor and reward mechanisms in the rat.

Reavill C, Hatcher JP, Lewis VA, Sanger GJ, Hagan J. Reavill C, et al. Among authors: sanger gj. Eur J Pharmacol. 1998 Sep 18;357(2-3):115-20. doi: 10.1016/s0014-2999(98)00564-0. Eur J Pharmacol. 1998. PMID: 9797026

9

Pharmacological characterization of the vanilloid receptor in the rat dorsal spinal cord.

Wardle KA, Ranson J, Sanger GJ. Wardle KA, et al. Among authors: sanger gj. Br J Pharmacol. 1997 Jul;121(5):1012-6. doi: 10.1038/sj.bjp.0701199. Br J Pharmacol. 1997. PMID: 9222561 Free PMC article.

10

5-Hydroxytryptamine and functional bowel disorders.

Sanger GJ. Sanger GJ. Neurogastroenterol Motil. 1996 Dec;8(4):319-31. doi: 10.1111/j.1365-2982.1996.tb00270.x. Neurogastroenterol Motil. 1996. PMID: 8959736 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results